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We report the isolation of Staphylococcus aureus with decreased susceptibility to glycopeptides in five CF patients and review the clinical and
microbiological features of these cases. Three patients presented with pulmonary exacerbation that may be attributed to these strains and two of
them were successfully treated using linezolid therapy. Glycopeptide-intermediate S. aureus (GISA) strains isolated in two patients were
susceptible to methicillin, while the three other patients harbored methicillin-resistant GISA. Rarely reported in CF, GISA may remain
underestimated due to the difficulty of detection, and both clinicians and microbiologists should be aware of the GISA emergence in CF patients’
population.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Glycopeptides; Resistance; Staphylococcus aureus; GISA; Cystic fibrosis1. Introduction
Glycopeptide-intermediate Staphylococcus aureus (GISA)
was first reported in a CF patient in 2002. Since then, 12
additional isolates showing heterogeneous resistance (hetero-
geneous GISA, hGISA) were reported in CF patients, suggest-☆ This study was presented in part at the 32nd European Cystic Fibrosis
Society Conference, Brest, France, 10–13 June 2009 [1].
⁎ Corresponding author at: UMR 5119, Equipe Pathogènes et Environnements,
U.F.R. Pharmacie, 15, avenue Charles Flahault BP 14491, 34093 Montpellier
Cedex 5, France. Tel.: +33 4 67 63 54 26; fax: +33 4 67 63 45 11.
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1569-1993/$ - see front matter © 2011 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2011.05.001ing that S. aureus with decreased susceptibility to glycopeptides
could be emergent in the CF population [2-4]. Clinical
implication of these strains was documented once, the first
reported strain being involved in bronchopulmonary exacerba-
tion [2-4]. We report here clinical and microbiological features
of GISA/hGISA isolation in five CF patients with the aim to
contribute to knowledge on these as-yet-rarely isolated strains
in CF and their implication in the respiratory status of patients.
Eight GISA/hGISA strains were isolated from these five
patients attending the CF center of the Montpellier University
Hospital, a large regional CF center caring for about 200
children and adults each year (95 adults and 110 children in
2009).d by Elsevier B.V. All rights reserved.
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colonization by a GISA/MRSA strain
In 2004, the 12-year-old patient was first colonized by
methicillin-resistant S. aureus (MRSA) and his clinical and
respiratory status rapidly worsened (body mass index (BMI)
11 kg/m2; forced expiratory volume in 1 s (FEV1), 37% pred)
requiring gastrostomy, continuous oxygen therapy and multiple
courses of IV antibiotics, of which eight included teicoplanin
(12 to 26 mg/kg/day for 48 h followed by 6 mg/kg/day for 14 to
21 days with monitoring of blood concentration). However, an
MRSA was still isolated from multiple samples until the end of
2004. In 2005, four courses of antimicrobial therapy with
linezolid for 15 days led to clinical improvement with a FEV1
increasing by 220 ml and no MRSA isolated from several
subsequent samples. A lung transplant was performed in
October 2005 (FEV1 44% pred) and the immediate post-
transplant clinical evolution was favorable (FEV1 76% pred,
January 2006). In the absence of sputum production, no
bacteriological analysis was performed until March 2006. In
March 2006, a GISA/MRSA strain was the only pathogen
cultured from a sputum sample (Table 1). The antimicrobial
susceptibility pattern was identical to that of strains isolated in
2004. Since the clinical status of the patient remained stable, no
treatment against MRSA was prescribed until 2007. In 2007, a
10% progressive decline in FEV1 was noted and the patient
received three courses of anti-MRSA treatment including pristina-
mycin and/or trimethoprim-sulfamethoxazole and/or rifampin
despite the absence of pulmonary exacerbation. However, several
MRSA strains with identical antibiotypeswere isolated untilMarch
2008. Among them, two strains isolated in May 2007 and March
2008were identified asGISA (Table 1). In June 2008, graft chronic
rejection occurred but no infectious signs were noted. The patient
died from respiratory failure in August 2009. In this case, two-year
GISA chronic colonization (fromMarch 2006 to March 2008) has
been documented on the basis of identical genotypic characteristics
of the three confirmed GISA isolates but the clinical implication
remains undetermined.
3. Case 2, a 24-year-old patient with successive isolation of
two unrelated GISA/MSSA responsible for pulmonary
exacerbation successfully treated by linezolid
In 2004, the clinical condition of patient 2, a 20-year-old,
worsened (BMI 17 kg/m2; FEV1 63% pred, moderate bronchi-
ectasis). Colonization by a methicillin-susceptible (MSSA) strain
was noted. The patient received four courses of antistaphylo-
coccal treatment per year, which did not include glycopeptide but
a combination of pristinamycin and/or rifampin and/or amoxicil-
lin-clavulanic acid, but no eradication of the strain was observed.
In 2007, Pseudomonas aeruginosa chronic colonization required
antimicrobial cure every 3 months according to the antibiogram.
In 2008, the patient experienced several episodes of pulmonary
exacerbation, his clinical status worsened and monthly IV
treatment alternatively against S. aureus (co-amoxiclav, 1 g
three times daily for 15 days) and P. aeruginosa (ciprofloxacin or
ceftazidime associated with tobramycin) was introduced incombination with nebulized tobramycin. The first GISA/MSSA
strainwas recognized during pulmonary exacerbation (FEV1 48%
pred) in August 2008. Retrospective analysis found an over-
looked GISA/MSSA strain with distinct antibiotype isolated
during an episode of pulmonary exacerbation (FEV1 33%pred) in
April 2008 (Table 1). Comparison of the genotypic characteristics
revealed the two GISA strains to be unrelated. In October 2008,
when GISA was confirmed, a linezolid course (600 mg b.i.d. for
15 days) led to clinical and respiratory function improvement.
The patient remains clinically stable and no S. aureus strains were
isolated from sputum samples for 1 year.
4. Case 3, a 19-year-old patient with pulmonary exacerbation
and teicoplanin treatment failure attributed to GISA/MSSA
and clinical improvement after linezolid therapy
Initial clinical decline was noted at the age of 16 years in
2004 (BMI 18 kg/m2, FEV1 78% pred, Bhalla score 10/25)
despite IV antimicrobial therapy against P. aeruginosa. Chronic
colonization by MRSA had been noted since May 2005 and
colonization by MSSA had been observed since March 2006. In
2006, regular treatment was started with an antimicrobial
regimen given every 3 months. The patient received teicoplanin
(400 mg daily for 2 days followed by 200 mg daily for 15 days)
in August 2007, plus pristinamycin and rifampin for 3 weeks in
September 2007. In November 2007, MSSA grown from
sputum culture during pulmonary exacerbation showed de-
creased susceptibility to glycopeptides (Table 1). From January
2008, three courses of linezolid were administered (600 mg b.i.d.
for 15 days every 3 months) due to treatment failure observed
after 15-day teicoplanin treatment, leading to clinical improve-
ment. The clinical status remained stable throughout 2008 and no
S. aureus were isolated during an 8-month period.
5. Case 4, a 37-year-old patient with pulmonary exacerbation
attributed to GISA/MRSA after teicoplanin treatment
Colonization by MRSA occurred for 5 years (2004) in
addition to MSSA, P. aeruginosa and Aspergillus fumigatus
frequent recovery in the sputum samples. FEV1 was relatively
stable until 2007 (between 60 and 70% pred). In 2008, anti-
MRSA antibiotic treatment was added to antimicrobial
treatment against P. aeruginosa with linezolid in May 2008
(600 mg b.i.d. for 15 days) and teicoplanin in December 2008,
October 2009 and November 2009 (400 mg daily for 15 days
with monitoring of blood concentration) because of multiple
pulmonary exacerbations and constant recovery of MRSA
from sputum samples. A GISA/MRSA strain was isolated
in November 2009 after 17 days of a combination of IV
ceftazidime, tobramycin and teicoplanin given for the treatment
of pulmonary exacerbation (FEV1 43% pred) (Table 1). The
patient refused any additional intravenous antimicrobial
therapy. Oral combination of fusidic acid and minocycline
was started for 15 days despite resistance to both drugs
observed on the antibiogram, in combination with nebulized
colimycin. Clinical status improved, probably due to associated
aerosol therapy, but MRSA was not eradicated.
Table 1
Clinical and microbiological features of the cases of GISA/hGISA isolation in CF patients in this study a.
Characteristic Patient
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Patient
Sex F M M F F
CF genotype F508del/N1303K F508del/F508del F508del/F508del G542X/R792X F508del/F508del
Age at first S. aureus colonization 12 y Unknown (b20 y) Unknown (b15 y) Unknown (b29 y) 7 y
Age at first MRSA colonization 12 y No MRSA Unknown (b15 y) 31 y 7 y
Age at hGISA/GISA isolation 14 y 24 y 17 y 36 y 12 y
Therapeutic requirements within
the 6 months preceding the
isolation of GISA (excluding
nebulized agents)
Teicoplanin, Levofloxacin, Ceftazidime,
Linezolid, Azithromycin, Amoxicillin-clavulanic
acid, Pristinamycin, Rifampin, Trimethoprim-
sulfamethoxazole
Ciprofloxacin, Tobramycin,
Ceftazidime, Amoxicillin-clavulanic
acid
Teicoplanin, Ciprofloxacin,
Tobramycin, Ceftazidime,
Pristinamycin, Rifampin,
Ticarcillin-clavulanic acid
Teicoplanin, Ciprofloxacin,
Levofloxacin, Tobramycin,
Ceftazidime, Trimethoprim-
sulfamethoxazole
Ciprofloxacin,
Tobramycin, Ticarcillin-
clavulanic acid
GISA/hGISA isolation b
Date March 2006 May 2007 March 2008 April 2008 August 2008 November 2007 November 2009 February 2010
Sample Sputum Sputum Sputum BAL Sputum Sputum Sputum Sputum
Clinical status at GISA/hGISA
recovery c
Stable Unstable
(Pulmonary
stenosis)
Unstable (Chronic
rejection)
Unstable Unstable Unstable Unstable Stable
Associated pathogens None GSSA/MRSA
Haemophilus
influenzae
Candida albicans Mucoid
P. aeruginosa
P. aeruginosa (mucoid
and non-mucoid)
MRSA
P. aeruginosa
(mucoid and non-mucoid)
P. aeruginosa GSSA/MRSA
P. aeruginosa
(mucoid and non-mucoid)
Methicillin-resistance phenotype MRSA MRSA MRSA MSSA MSSA MSSA MRSA MRSA
Initial detection mode d Antibiotype Systematic
testing
Systematic testing Retrospective
testing
Antibiotype Antibiotype Treatment failure Antibiotype
Vancomycin Etest MIC (mg/L) 4 2 3 2 2 3 2 1
Teicoplanin Etest MIC (mg/L) 8 2 3 2 6 3 3 6
Susceptibility/resistance to
gentamicin
R R R S S R S S
Susceptibility/resistance to rifampin R R R R R I R I
Resistance to other antimicrobial
agents e
KAN, TOB,
ERY, LIN,
TET, OFX
KAN, TOB,
ERY, LIN,
TET, OFX
KAN, TOB, ERY,
LIN, TET, OFX
KAN, TOB,
ERY
ERY, LIN, FOF KAN, TOB, ERY,
LIN, TET, OFX, TMP
KAN, TOB, ERY,
LIN, TET, OFX
KAN, TOB, ERY
Antimicrobial treatment No No No Piperacillin-
tazobactam,
Tobramycin
Ceftazidime,
Tobramycin,
Linezolid
Ciprofloxacin, Linezolid Fusidic acid, Minocycline
Colistin (aerosol)
Trimethoprim-
sulfamethoxazole
Outcome Stable Unstable Death August 2009 Unstable Stable Stable Improvement Stable
a All isolates were confirmed as GISA/hGISA by the National Reference Center for Staphylococci, Lyon, France by the reference method [10,18].
b GISA and hGISA phenotypes were not distinguished in this study because no strict delineation could be drawn between them, the heterogeneous phenotype being able to convert to the homogeneous phenotype and
conversely depending on subculturing conditions [18].
c Unstable clinical status, pulmonary exacerbation except where specified.
d In this study, initial detection by antibiotype includes positive screening for decreased susceptibility to glycopeptides using routine agar diffusion assays (i.e., disk diffusion assay showing inhibition zone around the
vancomycin or teicoplanin disk below the susceptibility breakpoint or inhibition diameter around the teicoplanin disk more than 3 mm smaller than that around the vancomycin disk or standard Etest MICs of vancomycin
or teicoplanin N2 μg/ml) and/or observation of suggestive resistance to gentamicin and/or rifampin.
e KAN, kanamycin; TOB, tobramycin; ERY, erythromycin; LIN, lincomycin; TET, tetracycline; OFX, ofloxacin; FOF, fosfomycin; TMP, trimethoprim-sulfamethoxazole; BAL, bronchoalveolar lavage fluid sample;
GSSA, glycopeptide-susceptible S. aureus; R, resistant; S, susceptible; NA, not applicable.
379
A
.
F
illeron
et
al.
/
Journal
of
C
ystic
F
ibrosis
10
(2011)
377–382
380 A. Filleron et al. / Journal of Cystic Fibrosis 10 (2011) 377–3826. Case 5, a 12-year-old patient with GISA/MRSA
colonization successfully treated by
trimethoprim/sulfamethoxazole
In this patient, intermittent colonization by MRSA has
been noted since the age of 7 years and colonization with
P. aeruginosa was observed once at the age of 9 years. Despite
colonization, lung function was stable (FEV1 between 80 and
100% pred) and nutritional status was normal. At the age of
12 years (February 2010), a GISA/MRSA strain was isolated
(Table 1). Despite a stable clinical status, co-trimoxazole
(sulfamethoxazole 800 mg/trimethoprim 160 mg t.i.d.) was
started for 15 days and no MRSA with decreased susceptibility
to glycopeptides has been isolated to date in this patient.
7. Antimicrobial susceptibility testing and confirmation
of decreased susceptibility to glycopeptides
Antimicrobial susceptibility testing was performed by disk
diffusion assay performed and interpreted according to the 2010
guidelines of the Antibiogram Committee of the French Society
for Microbiology (http://www.sfm-microbiologie.org/User-
Files/file/CASFM/casfm_2010.pdf). Standard vancomycin and
teicoplanin MICs were determined by the Etest method
(inoculum, 0.5 McFarland on Mueller-Hinton agar for 24 h;
breakpoint for susceptibility, ≤2 μg/ml). Results are reported in
Table 1. Decreased susceptibility to glycopeptides was con-
firmed for the eight isolates of this study by the National
Reference Center for Staphylococci, Lyon, France using the
population analysis profile–area under the curve (PAP-AUC)
reference method [5,6].
8. Genotypic analysis and evidence for the absence of
cross-contamination between patients
Using the DNA hybridization microarray Clondiag Staphy-
Type® (Alere) and Multi Locus Sequence Typing (MLST) [7],
we demonstrated: (i) the 2-year chronic colonization by a GISA
strain belonging to the Iberian MRSA clone and displaying the
following characteristics: ST 572, SCCmec I, agr1, ccr allotype
A1B1, in patient 1, (ii) the successive isolation of two unrelated
GISA/MSSA isolates in patient 2 (first isolate characteristics:
ST5, agr2; second isolate characteristics: ST931, agr1), (iii) the
absence of cross-contamination between the five patients, the
strains displaying distinct genotypes (patient 3, MSSA, ST247,
agr1; patient 4, strain belonging to the Lyon MRSA clone, ST8,
SCCmec IV, agr1, ccr allotype A2B2; patient 5, strain
belonging to the Cordobese MRSA clone, ST5, SCCmec I,
agr2, ccr allotype A1B1).
9. Discussion
Since their first description in Japan in 1997, GISA and
hGISA have been progressively reported worldwide [5,8-10].
These strains have been previously associated with prolonged
antibiotic therapy, prolonged hospitalization, treatment failure,
increased mortality and epidemic episodes with cross-contami-nation between patients [11]. In the routine practice of medical
microbiology, their detection is problematic, particularly when
strains displayed heterogeneous resistance and the isolates have
to be confirmed as GISA/hGISA by a time-consuming reference
method performed by a limited number of laboratories [12].
In CF patients, the first documented case of MRSA/GISA
isolation was reported in an 18-year-old patient with pulmonary
exacerbation who received successive courses of vancomycin
therapy [2]. Then, Cafiso et al. reported three hGISA/MRSA
strains in two CF patients (7 and 20 years old, respectively), i.e.,
in approximately 3% of CF patients harboring S. aureus [4], and
Dumitrescu et al. reported the characterization of eight MRSA
and one MSSA hGISA strains among 248 S. aureus isolates
(3.6%) from 235 CF patients [3] but no clinical documentation
is available for these cases. From these observations, it could be
assumed that GISA/hGISA strains are emerging in CF patients.
Here we found hGISA/GISA strains in 4.7% of the patients
consulting the CF center of our institution and colonized/
infected by S. aureus (5 out of 106 patients). Despite the few
cases reported to date, some common characteristics between
the cases reported here and the literature could be noted like
persistence of GISA/hGISA strains in the airways of CF patients
as well as successive isolation of strains with different
phenotypic or genotypic characteristics [2,4]. To date, GISA/
hGISA strains were demonstrated in CF patients with ages
ranging from 7 to 36 years, colonized with S. aureus for at least
2 years and submitted to several courses of antimicrobial
regimens not always including glycopeptides [2,4, this study].
Risk factors for GISA infection previously identified included
vancomycin or teicoplanin treatment in the month and up to
6 months and MRSA isolation in the 3 months preceding the
GISA isolation [13]. These factors are respectively noted for
three and four patients in this study and documented for two and
one cases reported in the literature, suggesting that common risk
factors for selection of GISA strains might be observed for CF
and non-CF patients. It is worth noting that CF patients are
probably at high risk for GISA emergence because of modified
pharmacokinetic and pharmacodynamic properties of antimi-
crobial drugs constituting favorable conditions for subinhibitory
concentrations inducing the selection of strains with decreased
susceptibility to glycopeptides [14,15]. However, some patients,
like patient 2, did not receive glycopeptide treatment and/or were
not colonized by MRSA, suggesting that other factors might be
involved in the colonization/infection by GISA/hGISA strains in
a non-outbreak setting but these factors still have to be elucidated.
Owing to the difficulty of GISA/hGISA detection, some
previously reported microbiological characteristics might be
helpful for their recognition beside failure to glycopeptide
treatment. Most strains are MRSA, although decreased
susceptibility to glycopeptides may also develop in MSSA
strains, the latter representing less than 3% of GISA in France
[6,16,17]. Resistance to gentamicin and rifampin has been
previously reported in about half of the GISA/MRSA strains
while rarely encountered in GSSA/MRSA (less than 5% of the
strains in France) and may be considered as suggestive for
associated decreased susceptibility to glycopeptides [13,18]. To
our knowledge, only one GISA/MSSA isolate has been
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additional GISA/MSSA beside five GISA/MRSA. We showed
that resistance to gentamicin and/or rifampin could also be
suggestive for decreased susceptibility to glycopeptides in
MSSA, all strains being resistant or intermediate to rifampin and
four strains, including the three clonal MRSA strains in patient
1 and the MSSA strain recovered in patient 3, being resistant to
gentamicin. Finally, although this was not investigated by
genotypic analyses in this study, some of the GISA isolates
reported here may have arisen fromMRSA strains as observed in
previous studies [16,19]. Indeed, GISA/MRSA isolated in May
2007 in patient 1 was recovered in association with a second
MRSA strain fully susceptible to glycopeptide after PAP-AUC
analysis but showing an identical antimicrobial susceptibility
pattern to the other antimicrobial agents, suggesting that the
GISA/MRSA strain emerged from the GSSA/MRSA strain.
Similarly, it is highly probable that the GISA/MSSA strain
isolated in patient 3 derived from the MRSA strain colonizing the
patient by excision of the chromosomal cassette containing the
mecA gene because of an identical resistance pattern to agents
other than β-lactams.
As in the first reported case, pulmonary exacerbation could be
attributed at least in part to the hGISA/GISA strains in three out of
the five patients in our study, thereby confirming the potential
pathogenicity of these strains during CF [2]. However, we
underlined that the clinical implication of hGISA/GISA strains
during the course of CF remains particularly difficult to document
because of the frequent concomitant isolation of several
pathogens and the identification of hGISA/GISA strains in
patients chronically colonized or infected by glycopeptide-
susceptible S. aureus (GSSA). This was even more complicated
here by the difficulty to date the initial GISA/hGISA colonization/
infection due to unavailable isolates for retrospective analysis.
Therapeutic implications of GISA strains are a matter of concern,
particularly when MRSA strains with associated resistance to
several other families of antimicrobial agents are involved [20].
No recommendations for treatment of GISA infections are
currently published. Therapeutic success has been reported
using high doses of vancomycin administered by continuous
infusion and monitored by serum levels dosage in combination
with fusidic acid followed by 3-month oral treatment with
minocycline and fusidic acid [2]. In this study, linezolid, a second-
line drug for management of respiratory exacerbation due to S.
aureus, was successfully used in three patients whilst co-
trimoxazole led to GISA eradication in one patient with stable
clinical status [21]. However, these two antibiotics should be used
with caution in CF patients, as they were previously involved in
the emergence of linezolid-resistant and of persistent S. aureus
(small-colony variants), respectively [22-24].
10. Conclusion
We report here the highest rate of GISA/hGISA described to
date in the CF population, hGISA/GISA strains being found in
4.7% of the patients colonized/infected by S. aureus. However,
these strains are probably underestimated because their detection
remains difficult and additional studies including case–controlstudies are still needed to determine their incidence and clinical
implication in CF patients as well as risk factors for acquisition.
Despite growing knowledge onGISA/hGISA strains, such strains
remain belatedly and/or retrospectively recognized in CF.
Consequently, adapted antimicrobial treatment is usually delayed
due to the time to result of the reference method used to confirm
the resistance and colonized/infected patients may represent a
reservoir for spread of GISA/hGISA strains in the meanwhile.
Moreover, GISA detection in CF patients significantly narrows
the therapeutic options andmayworsen the clinical outcome. Due
to the increasing cases reporting that these strains might be
involved in exacerbation during CF, clinicians and microbiolo-
gists should remain aware of S. aureus isolates with particular
antimicrobial susceptibility profiles and/or patients with poor
clinical course or treatment failure and should perform GISA/
hGISA detection more systematically.
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